Pathogenesis, prediction and trials for the prevention of insulin-dependent (type 1) diabetes mellitus

Advanced Drug Delivery Reviews

Volumn 35, Issue 2-3, 1999, Pages 143-156

  Graves, Patricia M ^a   Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Beta cell autoantibody; Clinical trials; Diabetes; Glutamate decarboxylase; Insulin; Islet cell; Nicotinamide

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; NICOTINAMIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; CLINICAL TRIAL; HEREDITY; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0033046545     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00070-2     Document Type: Review

References (85)

1. American Diabetes Association, Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care 20 (1997) 1183-1197.
2. Eisenbarth G.S. Type I diabetes mellitus: a chronic autoimmune disease. N. Engl. J. Med. 314:1986;1360-1368.
3. Kaprio J., Tuomilehto J., Koshenvuo M., Romanov K., Reunanen A., Eriksson J., Stengard J., Kesaniemi Y.A. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia. 35:1993;1060-1067.
4. Kyvik K.O., Green A., Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. Br. Med. J. 311:1995;913-917.
5. P. Fain, G.S. Eisenbarth, Genetics of Type 1 diabetes, in: J. Baxter, M. New, S. Melmed, L. Martini (Eds.), Genetics in Endocrinology, Lippincott-Raven, Philadelphia (in press).
6. M. Rewers, J.M. Norris, Epidemiology of type I diabetes, in: G.S. Eisenbarth, K.J. Lafferty (Eds.), Type I Diabetes: Molecular, Cellular, and Clinical Immunology, Oxford University Press, New York, 1996, pp. 172-208.
7. Lorenzen T., Pociot F., Hougaard P., Nerup J. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia. 37:1994;321-327.
8. Todd J.A., Farrall M. Panning for gold: genome-wide scanning for linkage in type I diabetes. Hum. Mol. Genet. 5:1996;1443-1448.
9. Davies J.L., Kawaguchi Y., Bennett S.T., Copeman J.B., Cordell H.J., Pritchard L.E., Reed P.W., Gough S.C.L., Jenkins S.C., Palmer S.M., Balfour K.M., Rowe B.R., Farrall M., Barnett A.H., Bain S.C., Todd J.A. A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 371:1994;130-136.
10. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 40:1987;1-14.
11. Wolf E., Spencer K.M., Cudworth A.G. The genetic susceptibility to Type I (insulin dependent) diabetes: analysis of the HLA-DR association. Diabetologia. 24:1983;224-230.
12. Thomson G., Robinson W.P., Kuhner M.K., Joe S., MacDonald M.J., Gottschall J.L., Barbosa J., Rich S.S., Bertrams J., Baur M.P., Partanen J., Tait B.D., Schober E., Mayr W.R., Ludvigsson J., Lindblom B., Farid N.R., Thompson C., Deschamps I. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am. J. Hum. Genet. 43:1988;799-816.
13. Rotter J.I., Anderson C.E., Rubin R., Congleton J.E., Terasaki P.I., Rimoin D.L. HLA genotypic study of insulin-dependent diabetes. The excess of DR3/DR4 heterozygotes allows rejection of the recessive hypothesis. Diabetes. 32:1983;169-174.
14. Noble J.A., Valdes A.M., Cook M., Klitz W., Thomson G., Erlich H.A. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 caucasian, multiplex families. Am. J. Hum. Genet. 59:1996;1134-1148.
15. *04 variants to predisposition to or protection from insulin dependent diabetes mellitus is independent of DQ. J. Autoimmun. 9:1996;411-414.
16. *0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first degree relatives of patients with IDDM. Diabetes. 44:1995;608-613.
17. Caillat-Zucman S., Garchon H., Timsit J., Assan R., Boitard C., Dijilah-Saiah I., Bougnères P., Bach J.F. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J. Clin. Invest. 90:1992;2242-2250.
18. Rewers M., Bugawan T.L., Norris J.M., Blair A., Beaty B., Hoffman M., McDuffie R.S., Hamman R.F., Klingensmith G., Eisenbarth G.S., Erlich H.A. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia. 39:1996;807-812.
19. Rewers M., Norris J.M., Eisenbarth G.S., Erlich H.A., Beaty B., Klingensmith G., Hoffman M., Yu L., Bugawan T.L., Blair A., Hamman R.F., Groshek M., McDuffie R.S. Jr. Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (Daisy). J. Autoimmun. 9:1996;405-410.
20. Nepom G.T. Immunogenetics and IDDM. Diabetes Rev. 1:1993;93-103.
21. She J.X. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol. Today. 17:1996;323-329.
22. Verge C.F., Gianani R., Yu L., Pietropaolo M., Smith T., Jackson R.A., Soeldner J.S., Eisenbarth G.S. Late progression to diabetes and evidence for chronic b-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes. 44:1995;1176-1179.
23. Oldstone M.B.A. Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science. 239:1988;500-502.
24. Blom L., Dahlquist G., Nystrom L., Sandstrom A., Wall S. The Swedish Childhood Diabetes Study: social and perinatal determinants for diabetes in childhood. Diabetologia. 32:1989;7-13.
25. Gibbon C., Smith T., Egger P., Betts P., Phillips D. Early infection and subsequent insulin dependent diabetes. Arch. Dis. Child. 77:1997;384-385.
26. Borch-Johnson K., Joner G., Mandrup-Poulsen T.et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. Lancet. 2:1984;1083-1086.
27. Karjalainen J., Martin J.M., Knip M., Ilonen J., Robinson B.H., Savilahti E., Akerblom H.K., Dosch H.M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N. Engl. J. Med. 327:1992;302-307.
28. Norris J.M., Scott F.W. A meta-analysis of infant diet and insulin-dependent diabetes mellitus: do biases play a role? Epidemiology. 7:1996;87-92.
29. Norris J.M., Beaty B., Klingensmith G., Yu L., Hoffman M., Chase H.P., Erlich H.A., Hamman R.F., Eisenbarth G.S., Rewers M. Lack of association between early exposure to cow's milk protein and b-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). J. Am. Med. Assoc. 276:1996;609-614.
30. Norris J., Beaty B., Eisenbarth G.S., Rewers M. Could vitamin supplementation in infancy protect against beta-cell autoimmunity? Diabetes autoimmunity study in the young (DAISY). Diabetes. 45:1996;215A.
31. M. Rewers, M. Atkinson, The possible role of enteroviruses in diabetes mellitus, in: H.A. Rotbart (Ed.), Human Enterovirus Infections, ASM, Washington, 1996, pp. 353-385.
32. Graves P.M., Rewers M., Norris J.M., Pallansch M.A., Gerling I.C. The role of enteroviral infections in the development of IDDM: limitations of current approaches. Diabetes. 46:1997;161-168.
33. Richter W., Mertens T., Schoel B., Muir P., Ritzkowsky A., Scherbaum W.A., Boehm B.O. Sequence homology of the diabetes-associated autoantigen glutamate decarboxylase with coxsackie B4-2C protein and heat shock protein 60 mediates no molecular mimicry of autoantibodies. J. Exp. Med. 180:1994;721-726.
34. Clements G.B., Galbraith D.N., Taylor K.W. Coxsackie B virus infection and onset of childhood diabetes. Lancet. 346:1995;221-223.
35. Andreoletti L., Hober D., Hober-Vandenberghe C., Belaich S., Vantyghem M.C., Lefebvre J., Wattre P. Detection of coxsackie B virus RNA sequences in whole blood samples from adult patients at the onset of type I diabetes mellitus. J. Med. Virol. 52:1997;121-127.
36. Frisk G., Friman G., Tuvemo T., Fohlman J., Diderholm H. Coxsackie B virus IgM in children at onset of type I (insulin-dependent) diabetes mellitus: evidence for IgM induction by a recent or current infection. Diabetologia. 35:1992;249-253.
37. Helfand R.F., Gary H.E. Jr., Freeman C.Y., Anderson L.J., Pallansch M.A. Pittsburgh Diabetes Research Group. Serologic evidence of an association between enteroviruses and the onset of type 1 diabetes mellitus. J. Infect. Dis. 172:1995;1206-1211.
38. D'Alessio D.J. A case-control study of group B Coxsackievirus immunoglobulin M antibody prevalence and HLA-DR antigens in newly diagnosed cases of insulin-dependent diabetes mellitus. Am. J. Epidemiol. 135:1992;1331-1338.
39. Tuvemo T., Dahlquist G., Frisk G., Blom L., Friman G., Landin-Olsson M., Diderholm H. The Swedish childhood diabetes study III: IgM against coxsackie B viruses in newly diagnosed type 1 (insulin-dependent) diabetic children - no evidence of increased antibody frequency. Diabetologia. 32:1989;745-747.
40. Hyöty H., Hiltunen M., Knip M., Laakkonen M., Vähäsalo P., Karjalainen J., Koskela P., Roivainen M., Leinikki P., Hovi T., Åkerblom H.K. The Childhood Diabetes in Finland (DiMe) Study Group. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes. 44:1995;652-657.
41. Hiltunen M., Hyoty H., Knip M., Ilonen J., Reijonen H., Vahasalo P., Roivainen M., Lonnrot M., Leinikki P., Hovi T., Akerblom H.K. The Childhood Diabetes in Finland (DiMe) Study Group. Islet cell antibody seroconversion in children is temporally associated with enterovirus infections. J. Infect. Dis. 175:1997;554-560.
42. Dahlquist G.G., Ivarsson S., Lindberg B., Forsgren M. Maternal enteroviral infection during pregnancy as a risk factor for childhood IDDM. A population-based case-control study. Diabetes. 44:1995;408-413.
43. Dahlquist G., Frisk G., Ivarsson S.A., Svanberg L., Forsgren M., Diderholm H. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia. 38:1995;1371-1373.
44. Eberhardt M.S., Wagener D.K., Orchard T.J., LaPorte R.E., Cavender D.E., Rabin B.S., Atchison R.W., Kuller L.H., Drash A.L., Becker D.J. The Pittsburgh IDDM study. HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis. Diabetes. 34:1985;1247-1252.
45. Schernthaner G., Banatvala J.E., Scherbaum W., Bryant J., Borkenstein M., Schober E., Mayr W.R. Coxsackie-B-virus-specific IgM responses, complement-fixing islet-cell antibodies, HLA DR antigens, and C-peptide secretion in insulin-dependent diabetes mellitus. Lancet. 2:1985;630-632.
46. Fohlman J., Bohme J., Rask L., Frisk G., Diderholm H., Friman G., Tuvemo T. Matching of host genotype and serotypes of coxsackie B virus in the development of juvenile diabetes. Scand. J. Immunol. 26:1987;105-110.
47. Conrad B., Weissmahr R.N., Boni J., Arcari R., Schupbach J., Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type 1 diabetes. Cell. 90:1997;303-313.
48. Thai A., Eisenbarth G.S. Natural history of IDDM. Diabetes Rev. 1:1993;1-14.
49. D. Wegmann, D. Daniel, J.D. Peterson, K. Haskins, The role of T cells in beta cell damage in NOD mice and humans, in: G.S. Eisenbarth, K.J. Lafferty (Eds.), Type I Diabetes: Molecular, Cellular, and Clinical Immunology, Oxford University Press, New York, 1996, pp. 76-90.
50. Eisenbarth G.S. Mouse or man: is GAD the cause of type I diabetes? Diabetes Care. 17:1994;1-3.
51. Wegmann D.R., Norbury-Glaser M., Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur. J. Immunol. 24:1994;1853-1857.
52. Morgan D.J., Liblau R., Scott B., Fleck S., McDevitt H.O., Sarvetnick N., Lo D., Sherman L.A. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:1996;978-983.
53. Daniel D., Gill R.G., Schloot N., Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1995;1056-1062.
54. Peterson J.D., Haskins K. Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirement for CD8 T-cells. Diabetes. 45:1998;328-336.
55. Wang B., Gonzales A., Benoist C., Mathis D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 26:1996;1762-1769.
56. Wong F.S., Visintin I., Wen L., Flavell R.A., Janeway C.A. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183:1996;67-76.
57. Daniel D., Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA. 93:1996;956-960.
58. Ramiya V.K., Shang X., Pharis P.G., Wasserfall C.H., Stabler T.V., Muir A.B., Schatz D.A., Maclaren N.K. Antigen based therapies to prevent diabetes in NOD mice. J. Autoimmun. 9:1996;349-356.
59. Tian J., Atkinson M., Clare-Salzer M., Herschenfeld A., Forsthuber T., Lehmann P.V., Kaufman D. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin dependent diabetes. J. Exp. Med. 183:1996;1561-1567.
60. R. Gianani, G.S. Eisenbarth, Humoral autoimmunity, in: G.S. Eisenbarth, K.J. Lafferty (Eds.), Type I Diabetes: Molecular, Cellular, and Clinical Immunology, Oxford University Press, New York, 1996, pp. 209-229.
61. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., Chase H.P., Eisenbarth G.S. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J. Autoimmun. 9:1996;379-383.
62. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietroapolo M., Jackson R.A., Chase H.P., Eisenbarth G.S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 45:1996;926-933.
63. Yu L., Rewers M., Gianani R., Kawasaki E., Zhang Y., Verge C., Chase P., Klingensmith G., Erlich H., Norris J., Eisenbarth G.S. Anti-islet autoantibodies develop sequentially rather than simultaneously. J. Clin. Endocrinol. Metab. 81:1996;4264-4267.
64. Akerblom H.K., Paganus A., Teramo K., Saukkonen T., Knip M., Ilonen J.et al. Primary prevention of type I diabetes by nutritional intervention. Description of a pilot study (abstract). Autoimmunity. 15:1993;58.
65. Pociot F., Reimers J.I., Andersen H.U. Nicotinamide - biological actions and therapeutic potential in diabetes prevention. Diabetologia. 36:1993;574-576.
66. Elliott R.B., Pilcher C.C., Fergusson D.M., Stewart A.W. A population-based strategy to prevent insulin-dependent diabetes using nicotinamide. J. Pediatr. Endocrinol. Methods. 9:1996;501-509.
67. Carel J.-C., Boitard C., Eisenbarth G., Bach J., Bougnères P. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type I diabetic children. J. Autoimmun. 9:1996;739-745.
68. Herskowitz R.D., Jackson R.A., Soeldner J.S., Eisenbarth G.S. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J. Autoimmun. 2:1989;733-737.
69. Elliott R.B., Chase H.P. Prevention or delay of type I (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia. 34:1991;362-365.
70. Karounos D.G., Bryson J.S., Colhen D.A. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J. Clin. Invest. 100:1997;1344-1348.
71. Zhang J.Z., Davidson L., Eisenbarth G.S., Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA. 88:1991;10252-10256.
72. von Herrath M.G., Dyrberg T., Oldstone M.B.A. Oral insulin treatment suppresses virus-induced antigen-specific destruction of B cells and prevents autoimmune diabetes in transgenic mice. J. Clin. Invest. 98:1996;1324-1331.
73. Tisch R., Yang X., Liblau R.S., McDevitt H.O. Administering glutamic acid decarboxylase to NOD mice prevents diabetes. J. Autoimmun. 7:1994;845-850.
74. Elliott J.F., Qin H.Y., Bhatti S., Smith D.K., Singh R.K., Dillon T., Lauzon J., Singh B. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes. 43:1994;1494-1499.
75. Ramiya V.K., Lan M.S., Wasserfall C.H., Notkins A.L., Maclaren N.K. Immunization therapies in the prevention of diabetes. J. Autoimmun. 10:1997;287-292.
76. Ma S.W., Zhao D.L., Yin Z.Q., Mukherjee R., Singh B., Qin H.Y., Stiller C.R., Jevnikar A.M. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Medicine. 3:1997;793-796.
77. Bingley P.J., Christie M.R., Bonifacio E., Bonfanti R., Shattock M., Fonte M., Bottazzo G., Gale E.A.M. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes. 43:1994;1304-1310.
78. Hagopian W.A., Sanjeevi C.B., Kockum I., Landin-Olsson M., Karlsen A.E., Sundkvist G., Dahlquist G., Palmer J., Lernmark Å. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J. Clin. Invest. 95:1995;1505-1511.
79. Bonifacio E., Genovese S., Braghi S., Bazzigaluppi E., Lampasona V., Bingley P.J., Rogge L., Pastore M.R., Bognetti E., Bottazzo G.F., Gale E.A.M., Bosi E. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia. 38:1995;816-822.
80. Bingley P.J., Bonifacio E., Williams A.J.K., Genovese S., Bottazzo G.F., Gale E.A.M. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 46:1997;1701-1710.
81. 65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings, Diabetologia 40 (1997) 95-99.
82. Keller R.J., Eisenbarth G.S., Jackson R.A. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 341:1993;927-928.
83. Slover R.H., Eisenbarth G.S. Prevention of type I diabetes and recurrent B-cell destruction of transplanted islets. Endocrinol. Rev. 18:1997;241-258.
84. Ziegler A.G., Bachmann W., Rabl W. Prophylactic insulin treatment in relatives at high risk for type I diabetes. Diabetes Metab. Rev. 9:1993;289-293.
85. Lampeter E.F., Klinghammer A., Scherbaum W.A., Heinze E., Haastert B., Giani G., Koln H. the DENIS Group, The Deutsche Nicotinamide Intervention Study - DENIS: an attempt to prevent diabetes. Diabetes. 47:1998;980-984.